Barrington raised the firm's price target on Orthofix to $17 from $15 and keeps an Outperform rating on the shares after the company disclosed via an 8-K filing on Friday that CMS had reversed itself on its very recent 10% reimbursement cut within traditional Medicare for non-invasive bone growth stimulators. As a result, the firm is reverting to the model it had built prior to May 18, the analyst tells investors.
